Skip to main content
. Author manuscript; available in PMC: 2016 Apr 10.
Published in final edited form as: Cancer Lett. 2015 Jan 28;359(2):314–324. doi: 10.1016/j.canlet.2015.01.035

Fig. 4.

Fig. 4

Discriminating sera from early-stage PDAC patients, CP patients, stage I lung cancer patients, and from control individuals. Panel A, mass peaks are averages from 5 individual serum samples per category. Panel B, distinguishing sera of PDAC stage I + IIA patients, CP patients, stage I lung cancer patients, and control individuals based on significant “% PDAC patient serum peaks”. Panel C, test metrics (described in Materials and Methods) for data in panel B.